

**REYVOW- lasmiditan tablet**  
**Eli Lilly and Company**

-----  
**REYVOW (lasmiditan) tablets, for oral use, [CV in USA] - FOR EXPORT ONLY**  
**Initial U.S. Approval: 2020**

**PACKAGE LABEL - REYVOW 50 mg 4ct carton - FOR EXPORT ONLY**

NDC 0002-0265-04

4 tablets (1 card of 4 tablets)

REYVOW™

(lasmiditan)

tablets 50 mg

For oral use.

Each tablet contains 50 mg of lasmiditan.

Rx only

50 mg

Dispense enclosed Medication Guide to each patient.

Lilly



**PACKAGE LABEL - REYVOW 100 mg 4ct carton - FOR EXPORT ONLY**

NDC 0002-0632-04

4 tablets (1 card of 4 tablets)

REYVOW™

(lasmiditan)

tablets 100 mg

For oral use.

Each tablet contains 100 mg of lasmiditan.

Rx only

100 mg

Dispense enclosed Medication Guide to each patient.



## REYVOW

lasmiditan tablet

### Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:0002-0265
<b>Route of Administration</b>	ORAL	<b>DEA Schedule</b>	CV

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
<b>lasmiditan</b> (UNII: 76019WM792) (lasmiditan - UNII:76019WM792)	lasmiditan	50 mg

## Inactive Ingredients

Ingredient Name	Strength
<b>Microcrystalline cellulose</b> (UNII: OP1R32D61U)	
<b>Starch, corn</b> (UNII: O8232NY35J)	
<b>Croscarmellose Sodium</b> (UNII: M28OL1HH48)	
<b>Sodium Lauryl Sulfate</b> (UNII: 368GB5141J)	
<b>Magnesium Stearate</b> (UNII: 70097M6I30)	
<b>Polyvinyl Alcohol, Unspecified</b> (UNII: 532B59J990)	
<b>Titanium dioxide</b> (UNII: 15FIX9V2JP)	
<b>Polyethylene Glycol 3350</b> (UNII: G2M7P15E5P)	
<b>Talc</b> (UNII: 7SEV7J4R1U)	
<b>Ferrosoferric Oxide</b> (UNII: XMOM87F357)	

## Product Characteristics

<b>Color</b>	gray (light gray)	<b>Score</b>	no score
<b>Shape</b>	OVAL (oval)	<b>Size</b>	9mm
<b>Flavor</b>		<b>Imprint Code</b>	L50;4312
<b>Contains</b>			

## Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0002-0265-04	1 in 1 CARTON	08/21/2020	
1		4 in 1 BLISTER PACK; Type 0: Not a Combination Product		

## Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
Export only		08/21/2020	

## REYVOW

lasmiditan tablet

### Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:0002-0632
<b>Route of Administration</b>	ORAL	<b>DEA Schedule</b>	CV

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
<b>lasmiditan</b> (UNII: 760I9WM792) (lasmiditan - UNII:760I9WM792)	lasmiditan	100 mg

## Inactive Ingredients

Ingredient Name	Strength
Microcrystalline cellulose (UNII: OP1R32D61U)	
Starch, corn (UNII: O8232NY3SJ)	
Croscarmellose Sodium (UNII: M28OL1HH48)	
Sodium Lauryl Sulfate (UNII: 368GB5141J)	
Magnesium Stearate (UNII: 70097M6I30)	
Polyvinyl Alcohol, Unspecified (UNII: 532B59J990)	
Titanium dioxide (UNII: 15FIX9V2JP)	
Polyethylene Glycol 3350 (UNII: G2M7P15E5P)	
Talc (UNII: 7SEV7J4R1U)	
Ferrosoferric Oxide (UNII: XM0M87F357)	
Ferric Oxide Red (UNII: 1K09F3G675)	

## Product Characteristics

Color	purple (light purple)	Score	no score
Shape	OVAL	Size	12mm
Flavor		Imprint Code	L100;4491
Contains			

## Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0002-0632-04	1 in 1 CARTON	08/21/2020	
1		4 in 1 BLISTER PACK; Type 0: Not a Combination Product		

## Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
Export only		08/21/2020	

**Labeler** - Eli Lilly and Company (006421325)